Austar Lifesciences Limited Updated Consolidated Group Earnings Guidance for the six months ending 30 June 2023. For the period, the Group is expected to record a loss attributable to the owners of the Company of approximately RMB 40 million for the six months ended 30 June 2023, as compared with a profit attributable to the owners of the Company of approximately RMB 45.8 million for the six months ended 30 June 2022.